Teleflex Incorporated (TFX)
Chart Events
Performance Outlook
| Previous Close | 288.69 |
| Open | 290.95 |
| Bid | 115.22 x 800 |
| Ask | 399.00 x 1000 |
| Day's Range | 281.30 - 292.66 |
| 52 Week Range | 256.77 - 428.36 |
| Volume | |
| Avg. Volume | 369,032 |
| Market Cap | 13.459B |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | 31.42 |
| EPS (TTM) | 9.14 |
| Earnings Date | Apr 27, 2022 - May 02, 2022 |
| Forward Dividend & Yield | 1.36 (0.49%) |
| Ex-Dividend Date | May 13, 2022 |
| 1y Target Est | 359.10 |
- Benzinga
RBC Capital Sees Meaningful M&A Execution For This Critical Care-Focused Stock
Teleflex Inc (NYSE: TFX) hosted its Investor Day and issued plans for 2023-2025. RBC Capital Markets believe TFX is a stronger company delivering stable revenue growth in the M-HSDs, margin expansion, double-digit EPS growth, and strong FCF. It positions Teleflex to execute its capital allocation strategy more meaningfully in the future. TFX has low leverage and enough firepower to execute on ~$2 billion in M&A. The analysts expect a disciplined approach to accretive M&A that will accrue to the
- GlobeNewswire
Teleflex Hosts 2022 Analyst & Investor Day
WAYNE, Pa., May 20, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices, will provide an update on its business and address its 2023-2025 business growth strategy and financial goals during its 2022 Analyst & Investor Day today in New York City. A live webcast of the event presentations will begin at 10:00 a.m. ET and the accompanying presentation materials will be available at that time on the Company’s web site at teleflex.com. “Teleflex is
- GlobeNewswire
Teleflex Announces Regulatory Clearance for its UroLift® System in China for the Treatment of Benign Prostatic Hyperplasia (BPH)
Will expand patient access to BPH treatmentWAYNE, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has received National Medical Products Administration (NMPA) approval for its UroLift® System in China for treating benign prostatic hyperplasia (BPH). Treatment with the UroLift® System is a minimally invasive approach to treating BPH, commonly known as an enlarged prostate, a condition which may cau
